Skip to content

Examining the Impact of a Mindfulness Program on Anxiety in Pediatric Alopecia Areata

Anthony J. Gilding, Eden Ventura, Nimrita Sangha, Cathryn Sibbald

Pediatric Dermatology June 14, 2026 DOI: 10.1111/pde.70280 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pilot study Peer reviewed
Population Adolescent patients with alopecia areata and anxiety
Intervention Breathr mindfulness app
Duration 3-month period
Topics Anxiety Meditation
Key points Daily use of the Breathr mindfulness app provided limited benefits for a subset of adolescents with alopecia areata and anxiety over a three-month period.

Abstract

ABSTRACT Alopecia areata is an immune‐mediated disease resulting in non‐scarring hair loss and is associated with significant burden on mental health and quality of life. Mindfulness‐based stress‐reduction therapies have emerged as a potential intervention and have shown promising results, though studies of efficacy in adolescent populations are lacking. Thus, this pilot study aimed to determine if the daily use of the Breathr mindfulness app would improve anxiety in adolescent patients with AA over a 3‐month period. Our results demonstrate that daily use of the app provided limited benefits for a subset of adolescents with AA and anxiety.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Explore topics